Immunological failure in an HIV élite controller: possible role of indirect markers of inflammation and benefit of antiretroviral therapy
AIDS
.
2020 Mar 15;34(4):646-647.
doi: 10.1097/QAD.0000000000002459.
Authors
Giorgio Bozzi
1
,
Nicola Squillace
2
,
Anna Maria Peri
1
,
Antonio Muscatello
1
,
Ilaria Beretta
2
,
Valeria Micheli
3
,
Andrea Gori
1
4
,
Alessandra Bandera
1
4
Affiliations
1
Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University of Milan, Milan.
2
Infectious Diseases Unit, Azienda Socio Sanitaria Territoriale di Monza, San Gerardo Hospital, University of Milano-Bicocca, Monza.
3
Clinical Microbiology, Virology and Bioemergencies, ASST FBF-Sacco, Luigi Sacco Hospital.
4
Department of Pathophysiology and Transplantation, University of Milano, Milan, Italy.
PMID:
32108675
DOI:
10.1097/QAD.0000000000002459
No abstract available
Publication types
Case Reports
Letter
MeSH terms
Adult
Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
CD4-CD8 Ratio
HIV Infections / drug therapy
HIV Infections / immunology*
HIV Long-Term Survivors*
Humans
Inflammation / immunology
Male
Viral Load